^
CANCER:

Small Cell Lung Cancer

No biomarker
Small Cell Lung Cancer
durvalumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
atezolizumab
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
topotecan
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
lurbinectedin
Sensitive: A1 - Approval
No biomarker
Small Cell Lung Cancer
CAV
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
nivolumab
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
pembrolizumab
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
paclitaxel
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
docetaxel
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
temozolomide
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
etoposide oral
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
vinorelbine tartrate
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
gemcitabine
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
bendamustine
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
irinotecan
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
bevacizumab
Resistant: A2 - Guideline
No biomarker
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
cisplatin
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
carboplatin
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
carboplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
cisplatin + etoposide IV
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
carboplatin + gemcitabine
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
cisplatin + topotecan
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
cisplatin + irinotecan
Sensitive: A2 - Guideline
No biomarker
Small Cell Lung Cancer
trilaciclib
Sensitive: B - Late Trials
PD-L1 expression
Small Cell Lung Cancer
atezolizumab
Sensitive: B - Late Trials
No biomarker
Small Cell Lung Cancer
CS 2164
Sensitive: B - Late Trials
No biomarker
Small Cell Lung Cancer
nanoliposomal irinotecan
Sensitive: B - Late Trials
TMB-H
Small Cell Lung Cancer
nivolumab + ipilimumab
Sensitive: B - Late Trials
TMB-H
Small Cell Lung Cancer
nivolumab
Sensitive: B - Late Trials
HLA-DQB1*03:01
Small Cell Lung Cancer
durvalumab + CP-675206
Sensitive: B - Late Trials
HER-2 positive
Small Cell Lung Cancer
trastuzumab
Sensitive: C1 - Off-label
NTRK3 fusion
Small Cell Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK2 fusion
Small Cell Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
NTRK1 fusion
Small Cell Lung Cancer
larotrectinib
Sensitive: C1 - Off-label
PD-L1 expression
Small Cell Lung Cancer
pembrolizumab
Sensitive: C1 - Off-label
EGFR exon 19 deletion
Small Cell Lung Cancer
gefitinib
Sensitive: C1 - Off-label
PD-L1 expression
Small Cell Lung Cancer
sintilimab
Sensitive: C2 – Inclusion Criteria
WRN mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RPA1 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RECQL5 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RECQL4 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RECQL mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD51D mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD51C mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD51B mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD51 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD54L mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD52 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
RAD50 mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
NBN mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
BLM mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
MRE11A mutation
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
MYC amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
MYCN amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
ATM deletion
Small Cell Lung Cancer
olaparib
Sensitive: C2 – Inclusion Criteria
CDKN2A mutation + TP53 mutation
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
PD-L1 expression
Small Cell Lung Cancer
avelumab
Sensitive: C2 – Inclusion Criteria
DLL3 overexpression
Small Cell Lung Cancer
rovalpituzumab tesirine
Sensitive: C2 – Inclusion Criteria
RICTOR amplification
Small Cell Lung Cancer
AZD2014
Sensitive: C2 – Inclusion Criteria
MYCL amplification
Small Cell Lung Cancer
AZD1775
Sensitive: C2 – Inclusion Criteria
TMB-H + PD-L1 expression
Small Cell Lung Cancer
atezolizumab
Sensitive: C3 – Early Trials
DLL3 expression
Small Cell Lung Cancer
AMG 757
Sensitive: C3 – Early Trials
MCL1 underexpression
Small Cell Lung Cancer
cisplatin
Sensitive: C3 – Early Trials
RB1 mutation
Small Cell Lung Cancer
nivolumab
Resistant: C3 – Early Trials
SLFN11 expression
Small Cell Lung Cancer
ABT-888
Sensitive: C3 – Early Trials
TNFA elevation
Small Cell Lung Cancer
ipilimumab
Resistant: C3 – Early Trials
IL2 elevation
Small Cell Lung Cancer
ipilimumab
Sensitive: C3 – Early Trials
IL6 elevation
Small Cell Lung Cancer
ipilimumab
Resistant: C3 – Early Trials
SLFN11 expression
Small Cell Lung Cancer
temozolomide + ABT-888
Sensitive: C3 – Early Trials
PD-L1 expression
Small Cell Lung Cancer
RRx-001
Sensitive: C3 – Early Trials
MRC1 expression
Small Cell Lung Cancer
RRx-001
Sensitive: C3 – Early Trials
EGFR mutation
Small Cell Lung Cancer
EGFR inhibitor
Sensitive: C3 – Early Trials
CD276 overexpression
Small Cell Lung Cancer
DS-7300
Sensitive: C3 – Early Trials
PD-L1 negative
Small Cell Lung Cancer
pembrolizumab
Sensitive: C4 – Case Studies
EGFR exon 19 deletion + PTEN K237Cfs*17
Small Cell Lung Cancer
anlotinib
Resistant: C4 – Case Studies
EGFR exon 19 deletion + PTEN K237Cfs*17
Small Cell Lung Cancer
pembrolizumab + anlotinib
Resistant: C4 – Case Studies
EGFR exon 19 deletion + PTEN K237Cfs*17
Small Cell Lung Cancer
osimertinib
Resistant: C4 – Case Studies
FGFR1 amplification + RAF1 amplification + CDK6 amplification
Small Cell Lung Cancer
nivolumab
Resistant: C4 – Case Studies
FGFR1 amplification + RAF1 amplification + CDK6 amplification
Small Cell Lung Cancer
ponatinib
Resistant: C4 – Case Studies
FGFR1 amplification + RAF1 amplification + MYC amplification
Small Cell Lung Cancer
pazopanib
Sensitive: C4 – Case Studies
EGFR exon 19 mutation
Small Cell Lung Cancer
osimertinib
Sensitive: C4 – Case Studies
EGFR exon 21 mutation
Small Cell Lung Cancer
gefitinib
Sensitive: C4 – Case Studies
EGFR exon 19 deletion + TP53 mutation + RB1 mutation
Small Cell Lung Cancer
durvalumab
Resistant: C4 – Case Studies
EGFR exon 19 deletion + TP53 mutation + RB1 mutation
Small Cell Lung Cancer
gefitinib + anlotinib
Resistant: C4 – Case Studies
EGFR exon 19 deletion + EGFR T790M
Small Cell Lung Cancer
etoposide oral
Sensitive: C4 – Case Studies
MYC amplification
Small Cell Lung Cancer
talazoparib + GSK525762
Sensitive: D – Preclinical
DLL3 underexpression
Small Cell Lung Cancer
AMG 757
Sensitive: D – Preclinical
TP53 mutation
Small Cell Lung Cancer
AZD1775 + VIC-1911
Sensitive: D – Preclinical
FGFR1 amplification
Small Cell Lung Cancer
TAS 120 + TAS-117
Sensitive: D – Preclinical
RB1 mutation
Small Cell Lung Cancer
nivolumab + ipilimumab
Resistant: D – Preclinical
MYC amplification
Small Cell Lung Cancer
YPN005
Sensitive: D – Preclinical